DRIO
DarioHealth Corp.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-52/100
Last price
6.02
▲ 0.22 (3.79%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
5.80
Day high
6.21
Day low
6.02
Volume
7.63K
Market cap
$58.99M
P/E (TTM)
—
52W range
5.80 – 16.55
Trailing performance
Returnvs SPY
1W
-9.06%
-11.0%
1M
-16.85%
-18.0%
3M
-16.62%
-21.1%
6M
-5.49%
-23.7%
YTD
-47.10%
-61.3%
1Y
-63.18%
-79.6%
3Y
-90.82%
-173.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DRIO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.12M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 24, 26 | SHAKED YOAV Director |
STOCK | 54.00K | $0 | Direct |
| Sep 24, 26 | FRANCO-YEHUDA CHEN Chief Financial Officer |
STOCK | 95.00K | $0 | Direct |
| Sep 24, 26 | MATHEIS DENNIS Director |
STOCK | 44.00K | $0 | Direct |
| Sep 24, 26 | MCGRATH DENNIS M Director |
STOCK | 61.00K | $0 | Direct |
| Sep 24, 26 | PALUMBO JOHN R Director |
STOCK | 62.00K | $0 | Direct |
| Sep 24, 26 | STERN ADAM K. Director |
STOCK | 28.00K | $0 | Direct |
| Sep 24, 26 | KARAH HILA Director |
STOCK | 28.00K | $0 | Direct |
| Sep 24, 26 | RAPHAEL EREZ Chief Executive Officer |
STOCK | 297.00K | $0 | Direct |
| Jul 23, 26 | MATHEIS DENNIS Director |
BUY | 14.43K | $100.00K | Direct |
| Sep 18, 25 | STERN ADAM K. Director |
CONVERSION | 20.20K | $615.13K | Indirect |
| Sep 11, 25 | SHAKED YOAV Director |
STOCK | 20.00K | $0 | Direct |
| Sep 11, 25 | FRANCO-YEHUDA CHEN Chief Financial Officer |
STOCK | 5.00K | $0 | Direct |
| Sep 11, 25 | MATHEIS DENNIS Director |
STOCK | 20.00K | $0 | Direct |
| Sep 11, 25 | NELSON STEVEN CHARLES President |
STOCK | 30.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
FRANCO-YEHUDA CHEN |
Chief Financial Officer | 125.00K | Stock Award(Grant) |
KAPLAN JON H |
Director | 111.57K | Stock Award(Grant) |
KARAH HILA |
Director | 58.97K | Stock Award(Grant) |
MATHEIS DENNIS |
Director | 87.03K | Stock Award(Grant) |
MCGRATH DENNIS M |
Director | 88.74K | Stock Award(Grant) |
NELSON STEVEN CHARLES |
President | 34.75K | Stock Award(Grant) |
PALUMBO JOHN R |
Director | 66.50K | Stock Award(Grant) |
RAPHAEL EREZ |
Chief Executive Officer | 456.33K | Stock Award(Grant) |
SHAKED YOAV |
Director | 87.67K | Stock Award(Grant) |
STERN ADAM K. |
Director | 84.06K | Stock Award(Grant) |
Fundamentals
Market cap$58.99M
Enterprise value$77.44M
Revenue (TTM)$21.00M
Gross profit$12.93M
EBITDA$-29.71M
Net income$-7.00M
EPS (TTM)$-2.28
Free cash flow$-12.35M
Total cash$13.96M
Total debt$32.41M
Book value / share$7.50
Shares outstanding9.80M
Float6.91M
Short % of float0.82%
Dividend yield0.00%
Beta (5Y)1.18
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.38
PEG ratio—
Price / sales—
Price / book0.80
EV / revenue3.69
EV / EBITDA-2.61
Gross margin61.57%
Operating margin-125.15%
Profit margin-169.87%
Return on equity-59.91%
Return on assets-19.42%
Debt / equity58.84
Current ratio2.31
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $22.36M | $27.04M | $20.35M | $27.66M | -17.3% |
| Operating revenue | $22.36M | $27.04M | $20.35M | $27.66M | -17.3% |
| Cost of revenue | $9.69M | $13.77M | $14.37M | $18.00M | -29.6% |
| Gross profit | $12.66M | $13.27M | $5.98M | $9.65M | -4.5% |
| Research & development | $13.79M | $24.18M | $20.25M | $19.65M | -43.0% |
| Selling, general & admin | $35.53M | $46.83M | $41.92M | $46.82M | -24.1% |
| Total operating expense | $49.32M | $71.01M | $62.17M | $66.47M | -30.5% |
| Operating income | -$36.66M | -$57.74M | -$56.19M | -$56.81M | +36.5% |
| Net interest income | -$6.26M | -$3.29M | -$3.67M | -$6.04M | -90.5% |
| Pre-tax income | -$41.61M | -$44.60M | -$59.36M | -$62.19M | +6.7% |
| Tax provision | $105.00K | -$1.85M | $64.00K | $4.00K | +105.7% |
| Net income | -$41.71M | -$42.75M | -$59.43M | -$62.19M | +2.4% |
| Net income to common | -$61.73M | -$40.98M | -$63.51M | -$63.84M | -50.6% |
| Basic EPS | -10.12 | -12.27 | -38.60 | -50.80 | +17.5% |
| Diluted EPS | -10.12 | -12.27 | -38.60 | -50.80 | +17.5% |
| EBIT | -$38.59M | -$44.60M | -$56.19M | -$60.31M | +13.5% |
| EBITDA | -$35.45M | -$37.17M | -$51.20M | -$55.60M | +4.6% |
| Basic shares | 3.98M | 2.45M | 1.42M | 1.18M | +62.4% |
| Diluted shares | 3.98M | 2.45M | 1.42M | 1.18M | +62.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $21.80M | $27.76M | $36.80M | $49.36M | -21.5% |
| Cash & short-term investments | $26.02M | $28.46M | $36.80M | $49.36M | -8.6% |
| Accounts receivable | $2.14M | $4.80M | $3.15M | $6.42M | -55.4% |
| Inventory | $4.32M | $4.75M | $5.06M | $7.96M | -9.2% |
| Total current assets | $35.07M | $40.53M | $47.33M | $65.52M | -13.5% |
| Property, plant & equipment | $1.27M | $1.77M | $1.87M | $1.99M | -28.6% |
| Goodwill & intangibles | $73.36M | $76.19M | $47.04M | $51.56M | -3.7% |
| Total assets | $110.08M | $118.88M | $96.39M | $119.19M | -7.4% |
| Total current liabilities | $9.32M | $16.64M | $12.49M | $19.35M | -44.0% |
| Current debt | — | $5.45M | $3.95M | $8.82M | — |
| Long-term debt | $30.75M | $23.47M | $24.59M | $18.11M | +31.0% |
| Total debt | $31.75M | $30.19M | $29.54M | $28.05M | +5.2% |
| Total liabilities | $42.15M | $46.87M | $38.24M | $39.19M | -10.1% |
| Retained earnings | -$452.08M | -$390.34M | -$349.36M | -$285.85M | -15.8% |
| Shareholder equity | $67.92M | $72.02M | $58.14M | $80.00M | -5.7% |
| Working capital | $25.74M | $23.89M | $34.84M | $46.17M | +7.7% |
| Net tangible assets | -$5.44M | -$4.17M | $11.10M | $28.44M | -30.4% |
| Shares issued | 6.91M | 1.92M | 1.36M | 1.29M | +259.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$41.71M | -$42.75M | -$59.43M | -$62.19M | — | +2.4% |
| Depreciation & amortisation | $3.14M | $7.43M | $4.99M | $4.72M | — | -57.7% |
| Stock-based compensation | $9.37M | $15.80M | $19.70M | $16.98M | — | -40.7% |
| Change in working capital | $1.39M | -$2.47M | $4.07M | -$10.90M | — | +156.3% |
| Operating cash flow | -$25.94M | -$38.56M | -$30.38M | -$47.84M | — | +32.7% |
| Capital expenditure | -$142.00K | -$138.00K | -$584.00K | -$573.00K | — | -2.9% |
| Investing cash flow | -$4.34M | -$8.93M | -$547.00K | -$573.00K | — | +51.4% |
| Share buybacks | — | — | $0 | -$134.00K | $0 | — |
| Financing cash flow | $24.31M | $38.53M | $18.25M | $61.94M | — | -36.9% |
| Free cash flow | -$26.08M | -$38.70M | -$30.96M | -$48.42M | — | +32.6% |
| End cash position | $21.80M | $27.76M | $36.80M | $49.47M | — | -21.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $5.18M | $5.58M | $5.23M | $5.01M | $5.37M | — | -7.3% |
| Operating revenue | $5.18M | $5.58M | $5.23M | $5.01M | $5.37M | — | -7.3% |
| Cost of revenue | $1.99M | $2.38M | $2.43M | $1.99M | $2.40M | — | -16.7% |
| Gross profit | $3.19M | $3.20M | $2.80M | $3.02M | $2.96M | — | -0.3% |
| Research & development | $2.10M | $2.38M | $2.63M | $3.33M | $3.72M | — | -11.9% |
| Selling, general & admin | $7.57M | $8.12M | $8.73M | $9.17M | $8.44M | — | -6.8% |
| Total operating expense | $9.67M | $10.51M | $11.37M | $12.50M | $12.16M | — | -8.0% |
| Operating income | -$6.48M | -$7.31M | -$8.56M | -$9.48M | -$9.20M | — | +11.4% |
| Net interest income | -$1.01M | -$883.00K | -$4.94M | -$1.01M | $206.00K | — | -14.0% |
| Pre-tax income | -$7.60M | -$8.19M | -$8.95M | -$10.47M | -$12.99M | — | +7.3% |
| Tax provision | $328.00K | $57.00K | $83.00K | $0 | $0 | — | +475.4% |
| Net income | -$7.92M | -$8.25M | -$9.03M | -$10.47M | -$12.99M | — | +3.9% |
| Net income to common | -$7.92M | -$8.25M | -$10.25M | -$18.86M | -$18.56M | — | +3.9% |
| Basic EPS | 0.85 | -1.25 | — | -2.96 | 3.54 | -2.87 | +168.0% |
| Diluted EPS | 0.85 | -1.25 | — | -2.96 | 3.54 | -2.87 | +168.0% |
| EBIT | -$6.47M | -$7.04M | -$7.85M | -$9.31M | -$9.20M | — | +8.1% |
| EBITDA | -$5.96M | -$6.52M | -$7.32M | -$8.76M | -$8.40M | — | +8.6% |
| Basic shares | 9.34M | 6.58M | — | 3.14M | 2.48M | 2.37M | +42.0% |
| Diluted shares | 9.34M | 6.58M | — | 3.14M | 2.48M | 2.37M | +42.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6.63M | $14.98M | $21.80M | $31.91M | $21.95M | — | -55.7% |
| Cash & short-term investments | $13.96M | $20.01M | $26.02M | $31.91M | $21.95M | — | -30.2% |
| Accounts receivable | $1.55M | $2.22M | $2.14M | $2.38M | $2.56M | — | -30.2% |
| Inventory | $3.72M | $4.17M | $4.32M | $4.87M | $4.61M | — | -10.9% |
| Total current assets | $22.13M | $28.73M | $35.07M | $42.19M | $32.17M | — | -23.0% |
| Property, plant & equipment | $1.53M | $1.12M | $1.27M | $1.32M | $1.47M | — | +37.0% |
| Goodwill & intangibles | $72.43M | $72.89M | $73.36M | $73.83M | $74.31M | — | -0.6% |
| Total assets | $96.59M | $103.28M | $110.08M | $117.73M | $108.33M | — | -6.5% |
| Total current liabilities | $9.58M | $9.36M | $9.32M | $9.28M | $9.75M | — | +2.4% |
| Current debt | — | — | — | — | — | $10.29M | — |
| Long-term debt | $31.06M | $30.93M | $30.75M | $30.62M | $30.50M | — | +0.4% |
| Total debt | $32.41M | $31.82M | $31.75M | $31.64M | $31.62M | — | +1.9% |
| Total liabilities | $41.50M | $40.90M | $42.15M | $42.79M | $44.34M | — | +1.5% |
| Retained earnings | -$468.25M | -$460.33M | -$452.08M | -$441.83M | -$422.97M | — | -1.7% |
| Shareholder equity | $55.09M | $62.38M | $67.92M | $74.93M | $63.99M | — | -11.7% |
| Working capital | $12.55M | $19.38M | $25.74M | $32.91M | $22.42M | — | -35.2% |
| Net tangible assets | -$17.34M | -$10.52M | -$5.44M | $1.10M | -$10.32M | — | -64.9% |
| Shares issued | 7.30M | 7.30M | 6.91M | 6.77M | 2.27M | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$7.92M | -$8.25M | -$9.03M | -$10.47M | -$12.99M | +3.9% |
| Depreciation & amortisation | $515.00K | $524.00K | $534.00K | $546.00K | $802.00K | -1.7% |
| Stock-based compensation | $632.00K | $1.44M | $2.04M | $2.95M | $2.04M | -56.1% |
| Change in working capital | $673.00K | $313.00K | $1.27M | -$465.00K | $1.49M | +115.0% |
| Operating cash flow | -$6.08M | -$6.03M | -$5.89M | -$7.35M | -$6.03M | -1.0% |
| Capital expenditure | -$38.00K | -$31.00K | -$26.00K | -$41.00K | -$44.00K | -22.6% |
| Investing cash flow | -$2.29M | -$826.00K | -$4.23M | -$41.00K | -$44.00K | -176.9% |
| Financing cash flow | $0 | $0 | -$19.00K | $17.39M | $124.00K | — |
| Free cash flow | -$6.12M | -$6.06M | -$5.91M | -$7.39M | -$6.08M | -1.1% |
| End cash position | $6.63M | $14.98M | $21.80M | $31.91M | $21.95M | -55.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.76 | -0.73 | +3.9% |
| Mar 2026 | -0.85 | -0.95 | -12.3% |
| Dec 2025 | -1.59 | -0.77 | +51.9% |
| Sep 2025 | -2.42 | -2.22 | +8.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.51 | 2 | $5.24M | +4.7% |
| Next quarter | -0.41 | 2 | $5.71M | +9.1% |
| Current year | -2.47 | 2 | $21.88M | -2.1% |
| Next year | -1.12 | 2 | $30.37M | +38.8% |
Analyst targets & ownership
Mean target$13.60
High target$28.00
Low target$8.00
Implied upside125.91%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy0 / 4
Hold1
Sell / Strong sell0 / 0
Held by insiders21.65%
Held by institutions9.11%
Institutions holding29
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
6.45
-6.71% from price
SMA 20
6.68
-9.90% from price
SMA 50
7.03
-14.38% from price
SMA 100
7.14
-15.72% from price
SMA 200
8.38
-28.12% from price
EMA 12
6.44
-6.59% from price
EMA 26
6.70
-10.10% from price
EMA 50
6.90
-12.78% from price
RSI (14)
38.6
Neutral
MACD (12,26,9)
-0.25
Hist -0.08
ATR (14)
0.35
5.74% of price
Realised vol 30D
65.5%
Annualised
Bollinger upper
7.37
20, 2σ
Bollinger lower
5.99
20, 2σ
50 / 200 cross
Death
7.03 vs 8.38
Trend bias
Below 200
-28.12%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.37
Less volatile than market
Correlation to SPY
0.06
Largely independent
Realised vol 30D
65.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-64.6%
Peak to trough
Max drawdown 5Y
-98.5%
Peak to trough
ATR 14
0.35
5.74% of price
Beta (reported)
1.18
5Y monthly, from filing
Short interest
Shares short
78.19K
Prior 82.83K
Change vs prior
-5.6%
Shorts covering
% of float
0.82%
Normal
% of shares out
0.80%
Against total outstanding
Days to cover
2.8
Liquid
Float
6.91M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 26 | Alliance Global Partners | INITIATED | — | Buy |
| Aug 12, 26 | TD Cowen | MAINTAINED | Hold | Hold |
| May 14, 26 | Stifel | MAINTAINED | Buy | Buy |
| May 13, 26 | TD Cowen | MAINTAINED | Hold | Hold |
| Mar 20, 26 | Stifel | MAINTAINED | Buy | Buy |
| May 19, 25 | Litchfield Hills | INITIATED | — | Buy |
| Mar 11, 25 | Stifel | MAINTAINED | Buy | Buy |
| Apr 1, 24 | Stifel | MAINTAINED | Buy | Buy |
| Aug 11, 23 | Alliance Global Partners | MAINTAINED | Buy | Buy |
| Jul 25, 23 | Stifel | MAINTAINED | Buy | Buy |
| May 12, 23 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Nov 16, 22 | Alliance Global Partners | MAINTAINED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay dateNov 18, 2019
Last split1:20
Split dateAug 28, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-04
Corporate Changes & Voting Matters
8-K · 2026-08-21
Periodic Financial Reports
10-Q · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-07-22
Corporate Changes & Voting Matters
8-K · 2026-07-10
Periodic Financial Reports
10-Q · 2026-05-13
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-04-13
Headlines
DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs
PR Newswire · 1d ago
Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives
PR Newswire · 20d ago
DarioHealth (DRIO) Q2 2026 Earnings Call Transcript
Motley Fool · 56d ago
DarioHealth Corp (DRIO) (Q2 2026) Earnings Call Highlights: Multi-Condition Platform Drives ...
GuruFocus.com · 57d ago
DarioHealth Corp. Q2 2026 Earnings Call Summary
Moby · 57d ago
DarioHealth Q2 Earnings Call Highlights
MarketBeat · 57d ago
DarioHealth Corp (DRIO) Q2 2026 Earnings Report Preview: What To Look For
GuruFocus.com · 57d ago
DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 57d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.